Teva reports first quarter 2022 financial results

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today reported results for the quarter ended march 31, 2022. mr. kÅre schultz, teva's president and ceo, said, 2022 is off to a solid start with the successful launch of a first generic version of revlimid® in the united states, and gains in market share for ajovy® both in the united states and in europe, where it has solidified its leadership position as the second leading brand. austedo® continues to
TEVA Ratings Summary
TEVA Quant Ranking